Johnson & Johnson Stock News

An emeritus Harvard Law School professor engaged in a years-long crusade to force shareholders to arbitrate their securities claims has a shot next month to convince Johnson & Johnson investors at their annual meeting to give up their right to file class actions.

Despite the S&P 500 Index, the Dow Jones Industrial Average (DJIA) Index, and the NASDAQ Composite Index all trading in the green, numerous notable stocks such as Johnson & Johnson (NYSE:JNJ), Occidental…

Bernstein has downgraded Johnson and Johnson (JNJ) from outperform to market perform citing the uphill battle for its Janssen unit in the coming years.

Protagonist Therapeutics (NASDAQ: PTGX ) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc , a unit of Johnson & Johnson (NYSE: JNJ ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b … Full story available on Benzinga.com

Johnson & Johnson (NYSE: JNJ ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 1 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Johnson & Johnson. The company has an average price target of $176.0 with a high of $185.00 and a low of $161.00. Below is a summary of how these 4 analysts rated Johnson & Johnson over … Full story available on Benzinga.com

Wednesday afternoon''s top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.

Johnson & Johnson''s (JNJ) orthopaedics unit DePuy Synthes has added two new technologies to its ATTUNE knee restoration portfolio for natural knee functionsThe comapny''s two…

Las Vegas, USA, March 15, 2022 (GLOBE NEWSWIRE) -- Breast Implants Market is Contemplated to Surge at a Tremendous CAGR of 7.00% by 2026, Asserts DelveInsight The increase in demand for Breast Implants is predominantly attributed to the growing prevalence of breast cancer among the population across the globe. In addition, the rising number of people demanding cosmetic surgeries mainly women to enhance their aesthetic appeal could also be a potential factor for increasing the Breast Implants market. Moreover, an increase in the number of breast augmentation surgeries and technological advancement in the product portfolio is expected to bolster the Breast Implant market during the forecasted period. DelveInsight''s Breast Implants Market Insights and Forecast report provides the current and forecast of Breast Implants, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Breast Implants Market scenario.

NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNJ, GME, DAL, MRNA, and ZM. … Full story available on Benzinga.com

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson . Looking at options history for Johnson & Johnson (NYSE: JNJ ) we detected 21 strange trades. If we consider the specifics of each trade, it is accurate to state that 71% of the investors opened trades with bullish expectations and 28% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $140,982 and 18, calls, for a total amount of $1,498,474. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting … Full story available on Benzinga.com

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

Johnson & Johnson (JNJ) and three leading drug distributors in the U.S., Cardinal Health (CAH), McKesson Corporation (MCK), and AmerisourceBergen (ABC), continue to draw the ire…